Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update

21d ago, source: Nasdaq

About Pulmatrix, Inc.Pulmatrix is a clinical-stage biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other ...

Pulmatrix Inc PULM

14d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Pulmatrix Inc 2PU

6d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update

21d ago, source: Yahoo Finance

March 28, 2024 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious ...

Pulmatrix Inc

14d ago, source: U.S. News & World Report

REIT ETFs provide investors with income and the potential for capital appreciation. Here are seven to buy now.

Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update

21d ago, source: Stockhouse

3rd amendment to Cipla partnership resulted in the wind down of the PUR1900 Phase 2b study and a significant reduction in expected cash burn for Pulmatrix Cipla to take sole responsibility for ...

Pulmatrix Inc.

21d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Pulmatrix Inc.: Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update

20d ago, source: Finanznachrichten

March 28, 2024 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious ...

Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update

21d ago, source:

Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and ...